How much does a domestic hospital in Enxidiping cost?

Enasidenib is a targeted drug for relapsed or refractory acute myeloid leukemia (AML) carrying IDH2 mutations. It achieves the purpose of treatment by inhibiting the abnormal enzyme activity caused by IDH2 mutations, interfering with abnormal metabolic pathways, and promoting AML cell apoptosis.

Leukemia is a malignant tumor of the hematopoietic system. AML is one type and is common in adults. The disease is caused by the abnormal proliferation and maturation block of leukemia stem cells in the bone marrow. Its clinical manifestations include anemia, bleeding, infection, etc., which seriously affects the patient's quality of life and prognosis. As a targeted drug, ensidipine specifically targets AML patients carrying IDH2 mutations. Ensidipine can significantly improve the condition of AML patients by interfering with abnormal metabolic pathways.

However, ensidipine has not yet received marketing approval in China, so the drug cannot be purchased in domestic hospitals. Patients need to purchase ensidipine through overseas channels, and the price in the overseas market is about 2,000 yuan. These generic drugs usually come from countries such as Laos and Bangladesh and have basically the same ingredients as the original drugs.

Although ensidipine has shown good efficacy in the treatment ofAML, its price is relatively high, which poses certain challenges to patients' affordability. Therefore, patients need to consider carefully when purchasing drugs and choose reputable supply channels to ensure the quality and safety of the drugs.

In general, ensidipine, as an important drug for targeted treatmentAML, has not yet been launched in China, so domestic hospitals cannot purchase it. Patients need to purchase through overseas channels and pay attention to price and quality issues to ensure the effectiveness and safety of the drugs.